Previous 10 | Next 10 |
Preliminary data from the Phase 1 CYCLE-1 trial are expected during second half 2020 MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T c...
Celyad (NASDAQ: CYAD ) updates on autologous NKG2D-based CAR-T development program for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). More news on: Celyad SA, Healthcare stocks news, Read more ...
Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary OptimAb manufacturing process Enrollment of DEPLETHINK trial evaluating CYAD-01 following preconditioning chemotherapy continues, wh...
MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that the Company has received €2.5 million in non-dilu...
Dr. Christian Homsy steps down from the Celyad Board of Directors as current CEO Filippo Petti is nominated into the role MONT-SAINT-GUIBERT, Belgium, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company f...
Celyad (NASDAQ: CYAD ) has received €8.5M in grants and non-dilutive funding from the Walloon Region of Belgium. More news on: Celyad SA, Healthcare stocks news, Stocks on the move, Read more ...
Funding will support the advancement of the Company’s autologous and allogeneic CAR-T cell therapy programs MONT-SAINT-GUIBERT, Belgium, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical com...
Hepion Pharmaceuticals HEPA +75% after CRV431 prevents cirrhosis in experimental model of severe liver disease. More news on: Bio-Path Holdings, Inc., Celyad SA, Westwater Resources, Inc., Stocks on the move, Read more ...
Gainers: SAExploration (NASDAQ: SAEX ) +85% . More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., Karuna Therapeutics, Inc., Stocks on the move, Read more ...
Celyad (NASDAQ: CYAD ): Q3 Net cash burn over of €6.1M. More news on: Celyad SA, Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Celyad SA Company Name:
CYAD Stock Symbol:
NASDAQ Market:
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced...
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Bid Price No...
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letterȁ...